Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Summary

The purpose of this study is to compare genotype-guided dosing to standard of care in patients with colorectal and pancreatic cancer with UGT1AI intermediate or UGT1A usual genotypes. Irinotecan is a chemotherapy drug that has been approved by the FDA to treat colorectal cancer. UGT1A1 is a germline marker for a liver enzyme that may predict irinotecan sensitivity. This is a randomized trial, which means that patients will be randomly assigned (by chance) into one of the treatment groups.

General Information

NCT#: NCT05391126
Study ID: MCC-22-GI-125-PMC
Trial Phase: Phase I

Trial Sponsor: Reema A. Patel, University of Kentucky
Therapies Used in This Trial: Irinotecan

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search